

Research predicts how patients are likely to respond to DNA drugs

September 19 2017



3-D Illustration of DNA molecule. Credit: Northumbria University

Research carried out by academics at Northumbria University, Newcastle could lead to improvements in treating patients with diseases caused by mutations in genes, such as cancer, cystic fibrosis and potentially up to 6,000 other inherited conditions.

By using virus genomics (genetic material), big data analysis and coding,



the experts have devised a technique for predicting how patients are likely to respond to treatments that directly target mutated genes, without even coming into contact with the patient. The method has direct application on DNA-based drugs currently on the market, 32 drugs in clinical trials, as well as future therapies such as genome editing.

The researchers achieved this by using a culture of human liver cancer cells that contain a non-infectious version of the Hep C virus, and drugs that treat Hep C by cutting and destroying its genome. As the Hep C virus is not good at copying its genome, it creates tens of billions of variants of itself in these cells: this is similar to the genetic variation which could be found in the wider population. The experts then tested the drugs on the cultures, and examined the impact of each of these drugs on each individual variant of Hep C, to determine which drugs work on which variants, and to what extent.

Although these types of drugs are generally highly effective, they are expensive and do not work on all patients. The findings could now lead to more targeted and personalised treatment for patients using these types of drugs, so that they can be prescribed safely, and with greater confidence that they will work.

The technique could also have a significant impact on <u>drug</u> development as companies and doctors could know in advance which patients to select for clinical trials, with greater confidence that the drugs will work. This means clinical <u>trials</u> will be more likely to be successful, bringing new drugs faster to patients. Similarly, after <u>new drugs</u> are approved, doctors will be able to carry out a simple test, to prescribe them safely and with confidence that they will work.

Dr Sterghios A. Moschos, Associate Professor of Cellular and Molecular Sciences at Northumbria University, led the research. He said: "This is a real breakthrough in bringing these types of <u>gene therapies</u> faster to



patients, making them at the same time safer and more effective. At the moment there is no way of knowing which drug will work on which patient, other than essentially trial and error, and time. Not only is this costly and risky for the drugs companies, and those paying for the drug, it can also be a lengthy process for patients, with a risk of the treatment not working.

"The next steps are to look at how the technique can be used as a single predictive test for research and clinical use, enabling us to predict which patients might respond to certain types of gene therapies, and by how much, whether they are experimental or approved.

"It may also have a significant role to play in the future for a new type of gene <u>therapy</u> called gene editing; <u>clinical trials</u> on gene editing are about to start in the US to cut out diseased <u>genes</u> from <u>patients</u> and replace them with healthy one."

Dr Moschos' research findings are published in *Molecular Therapy—Nucleic Acids*.

More information: Pantazis I. Theotokis et al. Profiling the Mismatch Tolerance of Argonaute 2 through Deep Sequencing of Sliced Polymorphic Viral RNAs, *Molecular Therapy - Nucleic Acids* (2017). DOI: 10.1016/j.omtn.2017.08.010

Provided by Northumbria University

Citation: Research predicts how patients are likely to respond to DNA drugs (2017, September 19) retrieved 6 May 2024 from <u>https://medicalxpress.com/news/2017-09-patients-dna-drugs.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private



study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.